|
May
27 2009
--
Vertex Pharmaceuticals Initiates Phase 3 Registration Program for…The VX-770 registration program will consist of three clinical trials, including a primary 48-week Phase 3 trial that is currently open to enrollment of patients aged 12 years and older who carry the G551D mutation on at least one allele.
May
27 2009
--
Fox Chase Researchers First To Determine Structure In A Class Of Self-Regulating ProteinsOriginally posted in Cystic Fibrosis News From Medical News Today Sections of proteins previously thought to be disordered may in fact have an unexpected biological role – providing certain proteins room to move – according to a study published by researchers at Fox Chase Cancer Center in this month’s issue of the journal Structure (Cell Press).
|
|
©Uncle & Drunken Crayfish Productions 2011
www.DrunkenCrayfish.com
Visit our NEW site at
PocketBiker.com 
by Raelene
